Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 9 | 2022 | 232 | 3.460 |
Why?
|
| Furosemide | 3 | 2021 | 44 | 1.700 |
Why?
|
| Nephritis, Interstitial | 2 | 2020 | 14 | 1.350 |
Why?
|
| Critical Illness | 5 | 2022 | 191 | 1.280 |
Why?
|
| Kidney Failure, Chronic | 5 | 2020 | 365 | 1.000 |
Why?
|
| AIDS-Associated Nephropathy | 2 | 2018 | 4 | 0.900 |
Why?
|
| Kidney Transplantation | 4 | 2020 | 839 | 0.850 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 122 | 0.790 |
Why?
|
| Donor Selection | 1 | 2020 | 29 | 0.780 |
Why?
|
| Eosinophilia | 1 | 2020 | 47 | 0.750 |
Why?
|
| Disease Progression | 4 | 2020 | 1037 | 0.750 |
Why?
|
| Viral Load | 2 | 2018 | 127 | 0.730 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 121 | 0.700 |
Why?
|
| Delayed Graft Function | 1 | 2017 | 39 | 0.660 |
Why?
|
| Creatine | 1 | 2017 | 30 | 0.650 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2016 | 8 | 0.610 |
Why?
|
| Lymphoma, T-Cell | 1 | 2016 | 19 | 0.600 |
Why?
|
| Chylous Ascites | 1 | 2016 | 11 | 0.600 |
Why?
|
| Nose Neoplasms | 1 | 2016 | 25 | 0.590 |
Why?
|
| HIV Infections | 3 | 2018 | 775 | 0.590 |
Why?
|
| Tissue Donors | 1 | 2017 | 195 | 0.580 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 33 | 0.570 |
Why?
|
| Biopsy | 4 | 2020 | 538 | 0.570 |
Why?
|
| Immunologic Factors | 1 | 2015 | 87 | 0.540 |
Why?
|
| Models, Biological | 1 | 2019 | 980 | 0.540 |
Why?
|
| Biomarkers | 7 | 2022 | 1593 | 0.530 |
Why?
|
| Diuretics | 3 | 2021 | 96 | 0.520 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 186 | 0.500 |
Why?
|
| Creatinine | 5 | 2022 | 243 | 0.490 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 481 | 0.460 |
Why?
|
| Critical Care | 2 | 2016 | 263 | 0.460 |
Why?
|
| Kidney | 3 | 2020 | 945 | 0.430 |
Why?
|
| Neoplasms | 2 | 2020 | 1660 | 0.430 |
Why?
|
| Intensive Care Units | 3 | 2021 | 344 | 0.420 |
Why?
|
| Humans | 25 | 2022 | 68502 | 0.410 |
Why?
|
| Urinary Tract | 1 | 2010 | 10 | 0.400 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2010 | 30 | 0.400 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 1241 | 0.390 |
Why?
|
| Middle Aged | 11 | 2021 | 21116 | 0.390 |
Why?
|
| Glutathione Transferase | 1 | 2010 | 166 | 0.380 |
Why?
|
| Glomerular Filtration Rate | 4 | 2020 | 274 | 0.370 |
Why?
|
| Male | 14 | 2021 | 37252 | 0.340 |
Why?
|
| Prognosis | 3 | 2019 | 2093 | 0.340 |
Why?
|
| Risk Factors | 6 | 2022 | 5718 | 0.330 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 1852 | 0.330 |
Why?
|
| ROC Curve | 2 | 2019 | 392 | 0.320 |
Why?
|
| Heart Arrest | 2 | 2020 | 113 | 0.320 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1548 | 0.320 |
Why?
|
| Incidental Findings | 2 | 2020 | 42 | 0.320 |
Why?
|
| Risk Assessment | 3 | 2019 | 2004 | 0.320 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2010 | 450 | 0.300 |
Why?
|
| Kidney Diseases | 2 | 2020 | 307 | 0.290 |
Why?
|
| Female | 9 | 2021 | 37990 | 0.250 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 1465 | 0.240 |
Why?
|
| Early Diagnosis | 2 | 2016 | 122 | 0.240 |
Why?
|
| Lipoxins | 1 | 2002 | 4 | 0.240 |
Why?
|
| Receptor Cross-Talk | 1 | 2002 | 16 | 0.240 |
Why?
|
| Retrospective Studies | 4 | 2020 | 7263 | 0.230 |
Why?
|
| Glomerular Mesangium | 1 | 2002 | 53 | 0.230 |
Why?
|
| Electrolytes | 1 | 2021 | 47 | 0.220 |
Why?
|
| Adult | 6 | 2020 | 21373 | 0.220 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 248 | 0.210 |
Why?
|
| Platelet Count | 1 | 2021 | 100 | 0.210 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2020 | 21 | 0.200 |
Why?
|
| Exercise Test | 1 | 2021 | 242 | 0.200 |
Why?
|
| Urinalysis | 1 | 2020 | 27 | 0.200 |
Why?
|
| Nephrology | 1 | 2020 | 43 | 0.200 |
Why?
|
| Aged | 5 | 2021 | 14841 | 0.190 |
Why?
|
| Eosinophils | 1 | 2020 | 60 | 0.190 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 114 | 0.190 |
Why?
|
| Young Adult | 3 | 2020 | 5708 | 0.190 |
Why?
|
| Ireland | 1 | 2019 | 13 | 0.190 |
Why?
|
| Medical Oncology | 1 | 2020 | 110 | 0.190 |
Why?
|
| Sex Distribution | 1 | 2020 | 272 | 0.180 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 40 | 0.180 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 67 | 0.180 |
Why?
|
| RNA, Viral | 1 | 2018 | 93 | 0.180 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2018 | 43 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2020 | 2356 | 0.170 |
Why?
|
| Adenine | 1 | 2017 | 46 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 929 | 0.160 |
Why?
|
| Hyperuricemia | 1 | 2017 | 13 | 0.160 |
Why?
|
| Liver Failure | 1 | 2017 | 27 | 0.160 |
Why?
|
| Prodrugs | 1 | 2017 | 54 | 0.160 |
Why?
|
| Analysis of Variance | 1 | 2020 | 1038 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2022 | 3702 | 0.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2016 | 20 | 0.150 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2016 | 24 | 0.150 |
Why?
|
| Paracentesis | 1 | 2016 | 25 | 0.150 |
Why?
|
| Calcimimetic Agents | 1 | 2015 | 2 | 0.150 |
Why?
|
| Prevalence | 1 | 2021 | 1609 | 0.150 |
Why?
|
| Torsades de Pointes | 1 | 2015 | 5 | 0.150 |
Why?
|
| Mortality | 1 | 2017 | 162 | 0.150 |
Why?
|
| Hypocalcemia | 1 | 2015 | 13 | 0.150 |
Why?
|
| Fatal Outcome | 1 | 2016 | 164 | 0.150 |
Why?
|
| Anti-HIV Agents | 1 | 2017 | 135 | 0.140 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2017 | 161 | 0.140 |
Why?
|
| Rituximab | 1 | 2015 | 61 | 0.140 |
Why?
|
| Podocytes | 1 | 2016 | 113 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 201 | 0.130 |
Why?
|
| Logistic Models | 1 | 2017 | 1419 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2017 | 400 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 848 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1139 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2014 | 285 | 0.110 |
Why?
|
| Organ Dysfunction Scores | 1 | 2010 | 13 | 0.100 |
Why?
|
| Kidney Tubules | 1 | 2010 | 80 | 0.100 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2010 | 48 | 0.100 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2010 | 84 | 0.100 |
Why?
|
| Lipid Peroxidation | 1 | 2010 | 94 | 0.100 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2010 | 250 | 0.090 |
Why?
|
| Algorithms | 1 | 2015 | 1194 | 0.090 |
Why?
|
| Treatment Outcome | 1 | 2020 | 7026 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 1752 | 0.070 |
Why?
|
| Adolescent | 1 | 2019 | 8903 | 0.070 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2005 | 15 | 0.070 |
Why?
|
| Mesangial Cells | 1 | 2005 | 37 | 0.070 |
Why?
|
| Renal Dialysis | 2 | 2017 | 174 | 0.070 |
Why?
|
| Cell Division | 2 | 2005 | 541 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 320 | 0.070 |
Why?
|
| Computational Biology | 1 | 2005 | 189 | 0.060 |
Why?
|
| Leukotriene D4 | 1 | 2002 | 2 | 0.060 |
Why?
|
| Receptors, Leukotriene | 1 | 2002 | 8 | 0.060 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2002 | 10 | 0.060 |
Why?
|
| Maleimides | 1 | 2002 | 15 | 0.060 |
Why?
|
| Cystatin C | 1 | 2022 | 3 | 0.060 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2002 | 10 | 0.060 |
Why?
|
| Dicarboxylic Acids | 1 | 2002 | 16 | 0.060 |
Why?
|
| Leukotriene Antagonists | 1 | 2002 | 13 | 0.060 |
Why?
|
| Interleukin-18 | 1 | 2022 | 16 | 0.060 |
Why?
|
| Lipocalin-2 | 1 | 2022 | 19 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2010 | 1615 | 0.060 |
Why?
|
| Albumins | 1 | 2022 | 72 | 0.060 |
Why?
|
| CHO Cells | 1 | 2002 | 161 | 0.060 |
Why?
|
| Cricetinae | 1 | 2002 | 262 | 0.060 |
Why?
|
| Tyrosine | 1 | 2002 | 196 | 0.050 |
Why?
|
| Indoles | 1 | 2002 | 145 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2002 | 269 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2005 | 2670 | 0.050 |
Why?
|
| Osmosis | 1 | 2020 | 38 | 0.050 |
Why?
|
| Animals | 3 | 2010 | 20811 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 58 | 0.050 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 93 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2002 | 1195 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 654 | 0.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 123 | 0.040 |
Why?
|
| Hospitalization | 2 | 2015 | 976 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 239 | 0.040 |
Why?
|
| Tenofovir | 1 | 2017 | 10 | 0.040 |
Why?
|
| Alanine | 1 | 2017 | 38 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2017 | 98 | 0.040 |
Why?
|
| Mice | 1 | 2010 | 8453 | 0.040 |
Why?
|
| Uric Acid | 1 | 2017 | 37 | 0.040 |
Why?
|
| Brain Injuries | 1 | 2020 | 268 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 536 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2077 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 85 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 791 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 1054 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1046 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1581 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1070 | 0.030 |
Why?
|
| Mitochondria | 1 | 2017 | 642 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 3256 | 0.020 |
Why?
|
| Isoantibodies | 1 | 2005 | 35 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2005 | 45 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2005 | 218 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2005 | 371 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 710 | 0.020 |
Why?
|
| United States | 1 | 2015 | 7333 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 2542 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 5267 | 0.010 |
Why?
|